Apolipoprotein C-II and C-III levels in hyperlipoproteinemia.
about
Apolipoprotein C3 SstI polymorphism and triglyceride levels in Asian IndiansTranscriptional regulation of apolipoprotein C-III gene expression by the orphan nuclear receptor RORalphaHuman apoC-IV: isolation, characterization, and immunochemical quantification in plasma and plasma lipoproteinsAn apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphismsHeavy marijuana users show increased serum apolipoprotein C-III levels: evidence from proteomic analysesExpression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditionsFunctional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemiaInsulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor.Associations between apolipoprotein CIII concentrations and microalbuminuria in type 2 diabetes.Complexities of plasma apolipoprotein C-III metabolismFibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibratesMechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.Lack of the Lysosomal Membrane Protein, GLMP, in Mice Results in Metabolic Dysregulation in LiverDetection of apolipoprotein C in human and rat enterocytes.Apolipoprotein CIII overexpression exacerbates diet-induced obesity due to adipose tissue higher exogenous lipid uptake and retention and lower lipolysis rates.Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial resultsEffects of dietary cholesterol and fatty acids on plasma lipoproteins.Radioimmunoassay of human arginine-rich apolipoprotein, apoprotein E. Concentration in blood plasma and lipoproteins as affected by apoprotein E-3 deficiency.Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids.Overexpression of apolipoprotein C-III decreases secretion of dietary triglyceride into lymphAnalysis of gene expression profile induced by hepatocyte nuclear factor 4alpha in hepatoma cells using an oligonucleotide microarray.Lipoprotein profile and prevalence of cardiovascular risk factors in urban Moroccan women.ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.Triglyceride-rich lipoprotein metabolism in women: roles of apoC-II and apoC-III.Apo CIII gene transcription is regulated by a cytokine inducible NF-kappa B element.Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins.Utilization of recombinant adenovirus and dominant negative mutants to characterize hepatocyte nuclear factor 4-regulated apolipoprotein AI and CIII expression.Multidimensional regulation of lipoprotein lipase: impact on biochemical and cardiovascular phenotypes.Storage of human plasma samples leads to alterations in the lipoprotein distribution of apoC-III and apoE.Genetic risk factors and ischaemic cerebrovascular disease: role of common variation of the genes encoding apolipoproteins and angiotensin-converting enzyme.Lipoprotein changes in relation to body mass index in Native American adolescents.γ-Secretase Inhibition Lowers Plasma Triglyceride-Rich Lipoproteins by Stabilizing the LDL Receptor.Proteomic Analysis of Avian Influenza A (H7N9) Patients within a Family Cluster.
P2860
Q21283798-E2E9C6C9-9F3F-4E81-8BB0-0642FA105567Q24290442-1408DB7B-4594-4466-A3A8-B9CAFAA4DD1BQ24300073-38735F2D-6D6F-4545-8D2A-90893252B9E8Q24562942-6312EE34-0F00-4ECD-84D5-77CA2EA245DFQ24654726-EC764D9C-8C60-45A5-82F4-822E2FB9523FQ28252652-E6E8E9F2-9DEE-43E9-BCC7-496AC8EE11D0Q28271254-0A1C04F4-9FF0-4AAA-81C8-94B4B95924DDQ33823946-8E06EC3A-6A00-4A0D-8755-AB722579311FQ33962626-2CFC5687-6899-4389-B3FB-49FFA3598CA8Q34172178-BF3BFBC5-A993-4C09-9C4F-EEDA7388FA7EQ34201490-3DFBF6BE-548A-4DC6-B2EF-4684CF660387Q35608640-89875C9D-13A2-4D53-9723-C5AB9B38E112Q35654453-16B2ED38-3B59-4D80-9DE3-F99F8E13D50EQ36203707-3A3D7078-04A5-42FB-8D98-C44D1CDF77E3Q36401998-C1DF5DCC-8E83-4A2A-9E6E-891C85C88C56Q36731776-2783A265-6AD2-45D2-907A-125B12361A68Q36983000-F81C88A5-BA17-423C-A9A5-C18DECAAEEBAQ37026784-9A777311-249C-4F79-AEA3-B40838C0D2ACQ37384407-B5F79474-2B01-4FD2-927D-5C027ECC8B88Q37727877-B57AE584-2EF5-4BC9-8448-B73A7334290FQ38292225-59D5B9AA-4130-471F-B6B3-98FFB99C9114Q38984136-12194438-8328-45AB-9FC3-A416F7FA917EQ39614082-4EBB7D0D-14CE-4E15-B715-8E45BE0C9CC6Q39631869-93FF14AC-504C-4B19-9F06-651C2C6BBBC1Q40229506-5527319E-D89D-4590-80E1-FBC29482A928Q40389936-B5FF9273-B24D-40DB-AC71-086B9D838CABQ41109529-E9113CBF-8960-4EDB-82C5-430AAB4A010AQ42400268-80AF7195-CE8E-427C-88F9-3A05072E7E2DQ44897940-EC2A0D90-33BD-4E1B-AE73-F5DF781EEDBFQ47830369-D3AB6880-D78F-4B01-A4A0-6175B92F0973Q51580777-DCC06896-EACF-47A0-91CF-E634208EB40CQ51735096-F1EEDB9E-7CBD-40D4-A858-8FF2091B1FBBQ55408163-290B4E37-CAEE-4747-9357-E799D0040A8C
P2860
Apolipoprotein C-II and C-III levels in hyperlipoproteinemia.
description
1979 nî lūn-bûn
@nan
1979年の論文
@ja
1979年論文
@yue
1979年論文
@zh-hant
1979年論文
@zh-hk
1979年論文
@zh-mo
1979年論文
@zh-tw
1979年论文
@wuu
1979年论文
@zh
1979年论文
@zh-cn
name
Apolipoprotein C-II and C-III levels in hyperlipoproteinemia.
@en
type
label
Apolipoprotein C-II and C-III levels in hyperlipoproteinemia.
@en
prefLabel
Apolipoprotein C-II and C-III levels in hyperlipoproteinemia.
@en
P2093
P1433
P1476
Apolipoprotein C-II and C-III levels in hyperlipoproteinemia.
@en
P2093
P304
P356
10.1016/0026-0495(79)90004-0
P577
1979-10-01T00:00:00Z